NRAS and melanoma: Over activity of the RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) pathway is the hallmark of the majority of melanomas, which is frequently due to mutations in BRAF or NRAS in approximately 50% and 20% of cases, respectively [1].